| Identification | Back Directory | [Name]
Mubritinib | [CAS]
366017-09-6 | [Synonyms]
CS-522
TAK 165
MUBRITINIB
TAK165;TAK-165
Mubritinib(TAK 165)
Mubritinib USP/EP/BP
(E)-4-((4-(4-(1H-1,2,3-Triazol-1-yl)butyl)phenoxy)methyl)-2-(4-(trifluoromethyl)styryl)oxazole
(E)-1-(4-(4-((2-(4-(trifluoromethyl)styryl)oxazol-4-yl)methoxy)phenyl)butyl)-1H-1,2,3-triazole
1-(4-(4-((2-((1E)-2-(4-(Trifluoromethyl)phenyl)ethenyl)-4-oxazolyl)methoxy)phenyl)butyl)-1H-1,2,3-triazole
1H-1,2,3-Triazole, 1-[4-[4-[[2-[(1E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]-
Mubritinib 1-(4-(4-((2-((1E)-2-(4-(Trifluoromethyl)phenyl)ethenyl)-4-oxazolyl)methoxy)phenyl)butyl)-1H-1,2,3-triazole
1-(4-(4-((2-((1E)-2-(4-(Trifluoromethyl)phenyl)ethenyl)-4-oxazolyl)methoxy)phenyl)butyl)-1H-1,2,3-triazole Mubritinib (TAK 165) | [Molecular Formula]
C25H23F3N4O2 | [MDL Number]
MFCD09954135 | [MOL File]
366017-09-6.mol | [Molecular Weight]
468.47 |
| Chemical Properties | Back Directory | [Melting point ]
158.0 to 162.0 °C | [Boiling point ]
620.9±65.0 °C(Predicted) | [density ]
1.25±0.1 g/cm3(Predicted) | [storage temp. ]
Store at +4°C | [solubility ]
DMSO : 50 mg/mL (106.73 mM; Need ultrasonic)H2O : < 0.1 mg/mL (insoluble) | [form ]
powder to crystal | [pka]
1.45±0.10(Predicted) | [color ]
White to Gray to Brown |
| Hazard Information | Back Directory | [Uses]
Treatment of cancer. | [Biological Activity]
Potent, irreversible human epithelial growth factor receptor 2 (ErbB2) inhibitor (IC 50 = 6 nM) that displays > 4000-fold selectivity over EGFR, FGFR, PDGFR, JAK1 and Src. Exhibits potent antiproliferative effects in ErbB2-overexpressing cancer cell lines (IC 50 = 5 nM in BT474 breast cancer cells) and significantly inhibits bladder, breast and prostate cancer xenograft growth in vivo . | [storage]
Store at -20°C |
|
|